» Articles » PMID: 15497688

Metabolism and Disposition of the HIV-1 Protease Inhibitor Lopinavir (ABT-378) Given in Combination with Ritonavir in Rats, Dogs, and Humans

Overview
Journal Pharm Res
Specialties Pharmacology
Pharmacy
Date 2004 Oct 23
PMID 15497688
Citations 45
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: The objective of this study was to examine the metabolism and disposition of the HIV protease inhibitor lopinavir in humans and animal models.

Methods: The plasma protein binding of [14C]lopinavir was examined in vitro via equilibrium dialysis technique. The tissue distribution of radioactivity was examined in rats dosed with [14C]lopinavir in combination with ritonavir. The metabolism and disposition of [14C]lopinavir was examined in rats, dogs, and humans given alone (in rats only) or in combination with ritonavir.

Results: The plasma protein binding of lopinavir was high in all species (97.4-99.7% in human plasma), with a concentration-dependent decrease in binding. Radioactivity was extensively distributed into tissues, except brain, in rats. On oral dosing to rats, ritonavir was found to increase the exposure of lopinavir-derived radioactivity 13-fold. Radioactivity was primarily cleared via the hepato-biliary route in all species (>82% of radioactive dose excreted via fecal route), with urinary route of elimination being significant only in humans (10.4% of radioactive dose). Oxidative metabolites were the predominant components of excreted radioactivity. The predominant site of metabolism was found to be the carbon-4 of the cyclic urea moiety, with subsequent secondary metabolism occurring on the diphenyl core moiety. In all the three species examined, the primary component of plasma radioactivity was unchanged lopinavir (>88%) with small amounts of oxidative metabolites.

Conclusions: Lopinavir was subject to extensive metabolism in vivo. Co-administered ritonavir markedly enhanced the pharmacokinetics of lopinavir-derived radioactivity in rats, probably due to inhibition of presystemic and systemic metabolism, leading to an increased exposure to this potent HIV protease inhibitor.

Citing Articles

Pharmacokinetic Evaluation of Neutral Sphinghomyelinase2 (nSMase2) Inhibitor Prodrugs in Mice and Dogs.

Ranjit A, Lee C, Tenora L, Mettu V, Pal A, Alt J Pharmaceutics. 2025; 17(1).

PMID: 39861669 PMC: 11768932. DOI: 10.3390/pharmaceutics17010020.


Deriving protein binding-corrected chemical concentrations for in vitro testing.

Kolli A Clin Transl Sci. 2023; 16(11):2123-2129.

PMID: 37605430 PMC: 10651662. DOI: 10.1111/cts.13616.


SARS-CoV-2 infection dysregulates the expression of clinically relevant drug metabolizing enzymes in Vero E6 cells and membrane transporters in human lung tissues.

Nwabufo C, Hoque M, Yip L, Khara M, Mubareka S, Pollanen M Front Pharmacol. 2023; 14:1124693.

PMID: 37180730 PMC: 10172598. DOI: 10.3389/fphar.2023.1124693.


Pharmacokinetic considerations to optimize clinical outcomes for COVID-19 drugs.

Nwabufo C, Bendayan R Trends Pharmacol Sci. 2022; 43(12):1041-1054.

PMID: 36374805 PMC: 9510059. DOI: 10.1016/j.tips.2022.09.005.


Pulmonary Delivery of Favipiravir in Rats Reaches High Local Concentrations without Causing Oxidative Lung Injury or Systemic Side Effects.

Akbal-Dagistan O, Sevim M, Sen L, Basarir N, Culha M, Erturk A Pharmaceutics. 2022; 14(11).

PMID: 36365193 PMC: 9696372. DOI: 10.3390/pharmaceutics14112375.


References
1.
Kempf D, Marsh K, Kumar G, Rodrigues A, Denissen J, McDonald E . Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir. Antimicrob Agents Chemother. 1997; 41(3):654-60. PMC: 163767. DOI: 10.1128/AAC.41.3.654. View

2.
Hsu A, Granneman G, Cao G, Carothers L, Japour A, Dennis S . Pharmacokinetic interaction between ritonavir and indinavir in healthy volunteers. Antimicrob Agents Chemother. 1998; 42(11):2784-91. PMC: 105944. DOI: 10.1128/AAC.42.11.2784. View

3.
Kempf D, Marsh K, Denissen J, McDonald E, Vasavanonda S, Flentge C . ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans. Proc Natl Acad Sci U S A. 1995; 92(7):2484-8. PMC: 42242. DOI: 10.1073/pnas.92.7.2484. View

4.
Denissen J, Grabowski B, Johnson M, Buko A, Kempf D, Thomas S . Metabolism and disposition of the HIV-1 protease inhibitor ritonavir (ABT-538) in rats, dogs, and humans. Drug Metab Dispos. 1997; 25(4):489-501. View

5.
Merry C, Barry M, Mulcahy F, Ryan M, Heavey J, Tjia J . Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV-infected patients. AIDS. 1997; 11(4):F29-33. DOI: 10.1097/00002030-199704000-00001. View